CF
IBRX icon

Corebridge Financial’s ImmunityBio IBRX Stock Holding History

Corebridge Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,873
Closed -$225K – 1291
2025
Q1 		$225K Buy
74,873
+2,906
+4% +$8.81K ﹤0.01% 2000
2024
Q4 		$184K Sell
71,967
-5,432
-7% -$22.6K ﹤0.01% 2236
2024
Q3 		$288K Buy
77,399
+1,159
+2% +$5.36K ﹤0.01% 2018
2024
Q2 		$482K Buy
+76,240
New +$503K ﹤0.01% 1712

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Corebridge Financial's IBRX Position: Q2 2025 in Review

Corebridge Financial sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 74,873 shares — an estimated $225K sold.

Corebridge Financial first reported a position in IBRX in Q2 2024 and held it in 4 quarters. The position peaked at $482K in Q2 2024. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Corebridge Financial reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 74,873 ImmunityBio shares in Q2 2025, an estimated $225K.
  • Corebridge Financial first reported a position in ImmunityBio in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ImmunityBio position peaked at $482K in Q2 2024.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.